Myriad Genetics Q1 revenue $200.4M, GAAP net loss $34.1M; reiterates FY guidance

MYRIAD GENETICS INC

2026-Q1 EPS reported -$0.36 revenue$200,400,000

GAAP net loss $34.1M ($0.36/sh); adjusted loss $0.09/sh; adjusted EBITDA negative $4.5M.
Revenue $200.4M (+2% YoY); Cancer Care +4%, Prenatal -15%, Mental Health +24%.
Test volumes 385k flat YoY; Cancer Care +13%, Prenatal -12%, Mental Health +7%.
Launched Precise MRD (ultrasensitive assay) and received FDA approval for MyChoice CDx as Zejula companion diagnostic.
Reiterated FY 2026 guidance: revenue $860-880M, adjusted EBITDA $37-49M, adj. gross margin 68-69%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

MYRIAD GENETICS INC reported first quarter ended March 31, 2026 results: revenue 200.4 million, net income net loss of $34.1 million, EPS loss per share was $0.09 per share. Guidance reaffirmed.

Period: first quarter ended March 31, 2026
Revenue: 200.4 million
Net income: net loss of $34.1 million
EPS: loss per share was $0.09 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

First quarter 2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth in average revenue per test.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

MYRIAD GENETICS INC filing history →

Source: SEC EDGAR

accession 0000899923-26-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.